Goldman Sachs Reinstates Buy on Relay Therapeutics, Announces $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter has reinstated a Buy rating on Relay Therapeutics (NASDAQ:RLAY) and set a price target of $20.

September 10, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has reinstated a Buy rating on Relay Therapeutics with a $20 price target, indicating a positive outlook for the stock.
The reinstatement of a Buy rating by a major financial institution like Goldman Sachs, along with a specific price target, is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100